These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38315285)

  • 61. USP18 Is Associated with PD-L1 Antitumor Immunity and Improved Prognosis in Colorectal Cancer.
    Jifu C; Lu L; Ding J; Lv M; Xia J; Wang J; Wang P
    Biomolecules; 2024 Sep; 14(9):. PubMed ID: 39334957
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting Nuclear Receptor Coactivator SRC-1 Prevents Colorectal Cancer Immune Escape by Reducing Transcription and Protein Stability of PD-L1.
    Hong Y; Chen Q; Wang Z; Zhang Y; Li B; Guo H; Huang C; Kong X; Mo P; Xiao N; Xu J; Ye Y; Yu C
    Adv Sci (Weinh); 2024 Sep; 11(33):e2310037. PubMed ID: 38953362
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Energy balance-related factors in childhood and adolescence and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status.
    Jenniskens JCA; Offermans K; Simons CCJM; Samarska I; Fazzi GE; van der Meer JRM; Smits KM; Schouten LJ; Weijenberg MP; Grabsch HI; van den Brandt PA
    Mol Carcinog; 2022 Dec; 61(12):1099-1115. PubMed ID: 36177801
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intertumoral Heterogeneity of CD3
    Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer.
    He S; Song W; Cui S; Li J; Jiang Y; Chen X; Peng L
    Cell Oncol (Dordr); 2023 Dec; 46(6):1731-1746. PubMed ID: 37402945
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Butyrate facilitates immune clearance of colorectal cancer cells by suppressing STAT1-mediated PD-L1 expression.
    Zhang Y; Tao Y; Gu Y; Ma Q
    Clinics (Sao Paulo); 2023; 78():100303. PubMed ID: 37931529
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
    Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
    Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 71. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 72. JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment.
    Cheng S; Li M; Li C; Dai Y; Zhuo J; Wang J; Qian J; Hao Z
    In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):382-396. PubMed ID: 38625487
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.
    Chen W; Dai G; Qian Y; Wen L; He X; Liu H; Gao Y; Tang X; Dong B
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751411
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CCL5-deficiency enhances intratumoral infiltration of CD8
    Zhang S; Zhong M; Wang C; Xu Y; Gao WQ; Zhang Y
    Cell Death Dis; 2018 Jul; 9(7):766. PubMed ID: 29991744
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    Cho YA; Ko SY; Suh YJ; Kim S; Park JH; Park HR; Seo J; Choi HG; Kang HS; Lim H; Park HY; Kwon MJ
    Curr Oncol; 2022 Apr; 29(5):2895-2908. PubMed ID: 35621626
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 80. NF-κB Activator 1 downregulation in macrophages activates STAT3 to promote adenoma-adenocarcinoma transition and immunosuppression in colorectal cancer.
    Wang S; Kuai Y; Lin S; Li L; Gu Q; Zhang X; Li X; He Y; Chen S; Xia X; Ruan Z; Lin C; Ding Y; Zhang Q; Qi C; Li J; He X; Pathak JL; Zhou W; Liu S; Wang L; Zheng L
    BMC Med; 2023 Mar; 21(1):115. PubMed ID: 36978108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.